The Story

“I saw my son lying on the ice and realized that, despite all of our technological advances, no one could tell me if my son was concussed or when it was safe for him to return to play.”

– Rich Uhlig, CEO and Founder, Quadrant Biosciences Inc.

This epiphany at a youth hockey game in a cold ice arena in Binghamton, NY, was the impetus for what became a five-year odyssey, during which Uhlig consumed all of the available literature on mild traumatic brain injury (mTBI) and tests, met with top mTBI researchers, clinicians and engineers, and self-funded ClearEdge. He also quickly discovered the assessments his team developed had far-reaching uses beyond mTBI and would be valuable as part of total brain health assessment.

“This is very personal to me. I started ClearEdge out of concern for my kids’ health and frustration with the tools available to baseline and assess concussion. As ClearEdge has developed, it’s turned into an effective tool for monitoring neurological disorders, balance-related issues and overall brain health.”

– Rich Uhlig, CEO and Founder, Quadrant Biosciences Inc.


The ClearEdge Brain Health Toolkit was developed and validated in cooperation with SUNY Upstate Medical Center’s Concussion Clinic and the state-of-the-art Motion Analysis Lab located in the Institute for Human Performance (IHP) in Syracuse, NY.

As part of the START-UP NY program, our headquarters is also strategically located within the IHP. This integral relationship with IHP allows us to maintain a close connection with the researchers and clinicians actively working in this space.

We Developed ClearEdge For:

  • Parents who are worried about their children’s health and afraid of the unseen consequences of brain injury.
  • Athletes who are concerned about the extent of an injury and confused about the timeline for recovery.
  • People of all ages who want to protect and prolong their quality of life and be on the alert for early onset of neurologic and balance-related disorders.
  • Healthcare providers who are frustrated with the lack of reliable, quantifiable tools for assessing balance and cognitive disorders, and are concerned about prematurely authorizing a patient’s return to activity.